Speak with a Defective Drug Specialist
Get answers to legal & medical questions
patient advocate

 

Latest News

Date posted: 12/17/2013

Authored by Chris Schroeder

For the past year, lawyers have been helping those who suffered internal bleeding while taking Pradaxa file lawsuits in a special federal multi district litigation court.
 
The expedited MDL court is supposed to flush out evidence on whether the maker of Pradaxa, Boehringer Ingelheim knew it was dangerous, and whether they concealed this information from patients who were later injured.
 
So far, this process has not gone well for the German drug maker. Studies continue to rank Pradaxa among the most dangerous drugs in the world. The latest court records show the number of Pradaxa lawsuits is rising fast. Finally, a judge recently fined Boehringer nearly $1 million for failing to comply with information requests.
 
The FDA approved the blood thinning drug Pradaxa in 2010 as a treatment to prevent blood clots and strokes in patients with atrial fibrillation. It was meant to replace the traditional blood thinner warfarin, which requires regular patient blood testing.
 
There is debate among experts, however, as to whether Pradaxa has higher risks of internal bleeding. The FDA has stated Pradaxa is as safe as warfarin. The Institute for Safe Medication Practices has examined the FDA’s own data and determined that patients taking Pradaxa may be nearly 5 times as likely to die from bleeding than those taking warfarin.
 
This year, a study from The Netherlands concluded atrial fibrillation patients taking blood thinners like Pradaxa may be 55% more likely to experience internal bleeding.
 
With more and more internal bleeding victims filing a Pradaxa lawsuit, cases have been consolidated to a special federal multidistrict litigation court in Illinois. The latest December court records show the number of cases filed has increased from 1,748 on November 18 to 1,936 on December 16th, a rise of nearly 11% in a month.
 
Now, Judge David Herndon, who is presiding over the Pradaxa bleeding lawsuits, has ordered Boehringer Ingelhiem to pay $931,000 in sanctions for withholding information from plaintiff’s lawyers and failing to preserve key evidence held by company executives.
 
Lawyers urge anyone who suffered internal bleeding after taking Pradaxa to learn their legal rights. If you or a family member were affected, contact DrugRisk.com today for more information or to speak with a lawyer.
 
Due to the specialized nature of these cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.